SPA Microgen (part of Nacimbio Holding of Rostec State Corporation) registered four new indications for RELATOX in Uzbekistan. Now the entire range of uses of this drug is available to consumers from the Republic of Uzbekistan, as in Russia.
In particular, to date Relatox has been approved by the Ministry of Health of Uzbekistan for the correction of wrinkles of the face and neck, as well as for the treatment of a number of neurological diseases, including blepharospasm, cervical dystonia (spastic torticollis), hyperhidrosis, chronic migraine in adults, upper and lower extremities muscle spasticity in children 2-17 years of age with infantile cerebral paralysis and focal spasticity of upper extremity muscles in adults.
The drug is the first original botulinum toxin type A developed in Russia. The mechanism of action of RELATOX is to block the production of the mediator responsible for neuromuscular impulse transmission. This leads to muscle relaxation and smoothing of facial wrinkles of the face and neck. In modern neurology, botulinum therapy is recognized as one of the biggest breakthroughs that has radically improved the results of treatment of movement and autonomic disorders, pain syndrome and other conditions.
SPA Microgen was the first in Russia to develop and market a botulinum toxin drug, which was originally used only in cosmetology to correct age-related facial changes. Today the drug is registered for eight indications, and its share in the Russian market has reached 35%, which makes the company one of the leaders in this field,” said Andrey Chicherin, Commercial Director of SPA Microgen.
According to Andrey Chicherin, Uzbekistan is among the priority markets for the company: "In recent years, the volume of supplies of medicines to the Republic has been kept at a high level - the list of exported products includes about 30 medicines of Microgen. Among them is the best-selling RELATOX, which has been available to local consumers since 2021. The drug accounts for about 10% of the company's sales in Uzbekistan”.
Registration of four new indications for the drug in Uzbekistan was based on data from clinical trials implemented in Russia. In 2021, there was publication of the results of the evaluation of RELATOX's effectiveness in such areas as the treatment of upper and lower extremities muscle spasticity in children 2-17 years with cerebral palsy and also cervical dystonia in patients between the ages of 18 and 65. In both cases, the results confirmed the high therapeutic efficacy of the drug. In the first study, the participants had a significant increase in the volume of active and passive movements and pain reduction, while in the second – a significant reduction in the severity of the disease and pain relief.
In 2022, SPA Microgen also published a study on the effectiveness and safety of RELATOX in the treatment of chronic migraine in patients aged 18-65. The study showed that the drug significantly improved the patients' condition: the duration of taking painkillers was reduced by 9 days per month, and concomitant migraine symptoms were also reduced.
At the same time, a study of the drug's effectiveness in the fight against neck wrinkles was completed. The project was implemented on the basis of four research centers in Moscow, Nizhny Novgorod, Krasnoyarsk and St. Petersburg. According to the results, the use of the drug can significantly reduce the severity of platysmal bands – vertical necklines, which appear due to hypertonus of the flat superficial muscle stretching from the chest line to the lower jaw.
